Polymorphisms in cMyc and p27 and Breast Cancer Risk
Author Information
Author(s): Jane C Figueiredo, Julia A Knight, Stewart Cho, Sevtap Savas, U Venus Onay, Laurent Briollais, Pamela J Goodwin, John R McLaughlin, Irene L Andrulis, Hilmi Ozcelik
Primary Institution: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
Hypothesis
Do polymorphisms in cMyc and p27 affect breast cancer risk and prognosis?
Conclusion
The p27-G109 allele may have a modest protective effect against breast cancer, but cMyc-N11S is not associated with risk or survival.
Supporting Evidence
- The p27-G109 allele was associated with a modest protective effect in adjusted analyses.
- cMyc-N11S was not associated with breast cancer risk or survival.
- Age at onset and family history did not significantly modify the association of these polymorphisms with breast cancer risk.
Takeaway
This study looked at two gene changes to see if they affect breast cancer risk. One change might help protect against cancer, but the other doesn't seem to matter.
Methodology
Data was collected from a large group of women with breast cancer and controls, using logistic regression and Cox models to analyze associations.
Potential Biases
Over-sampling of genetically predisposed individuals may limit generalizability.
Limitations
The study may have limited statistical power for survival analysis and focused only on two specific polymorphisms.
Participant Demographics
Majority were White pre-menopausal women, with a third having a first-degree family history of breast or ovarian cancer.
Statistical Information
P-Value
0.01
Confidence Interval
0.52–0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website